{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:42:24Z","timestamp":1762602144464,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100024370","name":"Governo Italiano Ministero dell'Istruzione dell'Universita e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100024370","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN2022_2022X2KWRK"],"award-info":[{"award-number":["PRIN2022_2022X2KWRK"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics and Research in Hepatology and Gastroenterology"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.clinre.2025.102566","type":"journal-article","created":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T12:12:36Z","timestamp":1741003956000},"page":"102566","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Long-term virological and clinical evaluation of chronic hepatitis B patients under nucleos(t)ide analogues therapy"],"prefix":"10.1016","volume":"49","author":[{"given":"Maria Stella","family":"Franz\u00e8","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlo","family":"Saitta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina","family":"Musolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaia","family":"Caccamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Filomia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Concetta","family":"Pitrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Cacciola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Teresa","family":"Pollicino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"10381","key":"10.1016\/j.clinre.2025.102566_bib0001","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"The Lancet"},{"issue":"2","key":"10.1016\/j.clinre.2025.102566_bib0002","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102566_bib0003","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.clinre.2025.102566_bib0004","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.jhep.2018.01.031","article-title":"Eight-year survival in chronic hepatitis B patients under long-term Entecavir or Tenofovir therapy is similar to the general population","volume":"68","author":"Papatheodoridis","year":"2018","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.clinre.2025.102566_bib0005","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1111\/liv.14155","article-title":"Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection","volume":"39","author":"Marcellin","year":"2019","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.clinre.2025.102566_bib0006","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1097\/MEG.0000000000001357","article-title":"Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir\/tenofovir","volume":"31","author":"Yu","year":"2019","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2025.102566_bib0007","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S2468-1253(20)30249-1","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","volume":"5","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102566_bib0008","doi-asserted-by":"crossref","first-page":"368","DOI":"10.3390\/v13030368","article-title":"HBV-Integration Studies in the clinic: role in the natural history of infection","volume":"13","author":"Pollicino","year":"2021","journal-title":"Viruses"},{"issue":"2","key":"10.1016\/j.clinre.2025.102566_bib0009","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.jhep.2018.02.032","article-title":"Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B","volume":"69","author":"Hsu","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2025.102566_bib0010","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.jhep.2018.07.018","article-title":"Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy","volume":"69","author":"Kim","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinre.2025.102566_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.coviro.2023.101360","article-title":"Hepatitis-B virus: replication cycle, targets, and antiviral approaches","volume":"63","author":"Nasser","year":"2023","journal-title":"Curr Opin Virol"},{"issue":"3","key":"10.1016\/j.clinre.2025.102566_bib0012","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2009.05.022","article-title":"Control of cccDNA function in hepatitis B virus infection","volume":"51","author":"Levrero","year":"2009","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.clinre.2025.102566_bib0013","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.clinre.2025.102566_bib0014","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1002\/hep.26376","article-title":"Reduction of hepatitis B surface antigen levels and hepatitis B surface antigen seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy","volume":"58","author":"Seto","year":"2013","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.clinre.2025.102566_bib0015","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1002\/hep4.1708","article-title":"Risks and benefits of discontinuation of nucleos(t)ide analogue treatment: a treatment concept for patients with HBeAg-negative chronic Hepatitis B","volume":"5","author":"Van B\u00f6mmel","year":"2021","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.clinre.2025.102566_bib0016","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1002\/hep.28280","article-title":"Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis","volume":"63","author":"Lok","year":"2016","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.clinre.2025.102566_bib0017","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1136\/gutjnl-2013-305517","article-title":"HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability","volume":"63","author":"Kim","year":"2014","journal-title":"Gut"},{"issue":"5","key":"10.1016\/j.clinre.2025.102566_bib0018","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.jhep.2017.07.012","article-title":"Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients \u2013 FINITE study","volume":"67","author":"Berg","year":"2017","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102566_bib0019","doi-asserted-by":"crossref","first-page":"e784","DOI":"10.1016\/j.cgh.2020.12.005","article-title":"Prediction of sustained response after nucleo(s)tide analogue cessation using HBsAg and HBcrAg levels: a multicenter study (CREATE)","volume":"20","author":"Sonneveld","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinre.2025.102566_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104992","article-title":"Perspectives on stopping nucleos(t)ide analogues therapy in patients with chronic hepatitis B","volume":"185","author":"Tout","year":"2021","journal-title":"Antiviral Res"},{"issue":"8","key":"10.1016\/j.clinre.2025.102566_bib0021","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1111\/jvh.13091","article-title":"Can we stop nucleoside analogues before HB sAg loss?","volume":"26","author":"Papatheodoridi","year":"2019","journal-title":"J Viral Hepat"},{"issue":"8","key":"10.1016\/j.clinre.2025.102566_bib0022","doi-asserted-by":"crossref","first-page":"677","DOI":"10.3851\/IMP3256","article-title":"DARING-B: discontinuation of effective Entecavir or Tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic Hepatitis B","volume":"23","author":"Papatheodoridis","year":"2018","journal-title":"Antivir Ther (Lond)"},{"issue":"2","key":"10.1016\/j.clinre.2025.102566_bib0023","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1002\/hep.29640","article-title":"Incidence and predictors of hepatitis B surface antigen seroclearance after cessation of nucleos(t)ide analogue therapy in hepatitis B e antigen\u2013negative chronic hepatitis B","volume":"68","author":"Jeng","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.clinre.2025.102566_bib0024","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1053\/j.gastro.2021.11.002","article-title":"Off-therapy response after nucleos(t)ide analogue withdrawal in patients with chronic hepatitis B: an international, multicenter, multiethnic cohort (RETRACT-B Study)","volume":"162","author":"Hirode","year":"2022","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinre.2025.102566_bib0025","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1002\/hep.25592","article-title":"Impact of hepatitis B virus (HBV) preS\/S genomic variability on HBV surface antigen and HBV DNA serum levels","volume":"56","author":"Pollicino","year":"2012","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.clinre.2025.102566_bib0026","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41575-022-00649-z","article-title":"A roadmap for serum biomarkers for hepatitis B virus: current status and future outlook","volume":"19","author":"Kramvis","year":"2022","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102566_bib0027","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.jhep.2016.08.009","article-title":"The role of quantitative hepatitis B surface antigen revisited","volume":"66","author":"Cornberg","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102566_bib0028","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s12072-019-09998-5","article-title":"Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B","volume":"14","author":"Mak","year":"2020","journal-title":"Hepatol Int."},{"issue":"1","key":"10.1016\/j.clinre.2025.102566_bib0029","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1053\/j.gastro.2023.09.033","article-title":"HBV DNA and HBsAg levels at 24 weeks off-treatment predict clinical relapse and HBsAg loss in HBeAg-negative patients who discontinued antiviral therapy","volume":"166","author":"Sonneveld","year":"2024","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.clinre.2025.102566_bib0030","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1053\/j.gastro.2010.04.052","article-title":"Hepatitis B surface antigen serum levels help to distinguish active from inactive hepatitis B virus genotype D carriers","volume":"139","author":"Brunetto","year":"2010","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.clinre.2025.102566_bib0031","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/infdis\/jir282","article-title":"Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss","volume":"204","author":"Zoutendijk","year":"2011","journal-title":"J Infect Dis"},{"issue":"4","key":"10.1016\/j.clinre.2025.102566_bib0032","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.jhep.2012.11.039","article-title":"Long-term hepatitis B surface antigen (HBsAg) kinetics during nucleoside\/nucleotide analogue therapy: finite treatment duration unlikely","volume":"58","author":"Chevaliez","year":"2013","journal-title":"J Hepatol"},{"issue":"7","key":"10.1016\/j.clinre.2025.102566_bib0033","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1002\/jmv.25080","article-title":"Relationship between serum quantitative HBsAg and HBV DNA levels in chronic hepatitis B patients","volume":"90","author":"Yang","year":"2018","journal-title":"J Med Virol"},{"issue":"1","key":"10.1016\/j.clinre.2025.102566_bib0034","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Electronic address: easloffice@easloffice.eu, European association for the study of the liver. EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.clinre.2025.102566_bib0035","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/apt.17105","article-title":"Review article: novel biomarkers in hepatitis B infection","volume":"56","author":"Lok","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.clinre.2025.102566_bib0036","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.jhep.2020.11.043","article-title":"Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients","volume":"74","author":"Garc\u00eda-L\u00f3pez","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102566_bib0037","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.jcv.2013.08.010","article-title":"Prediction of disease reactivation in asymptomatic hepatitis B e antigen-negative chronic hepatitis B patients using baseline serum measurements of HBsAg and HBV-DNA","volume":"58","author":"Martinot-Peignoux","year":"2013","journal-title":"J. Clin. Virol."},{"issue":"1","key":"10.1016\/j.clinre.2025.102566_bib0038","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jhep.2014.08.031","article-title":"Quantification of HBsAg in nucleos(t)ide-na\u00efve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study","volume":"62","author":"Zoulim","year":"2015","journal-title":"J Hepatol"},{"issue":"4","key":"10.1016\/j.clinre.2025.102566_bib0039","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.clinre.2025.102566_bib0040","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.jhep.2021.04.040","article-title":"The times they are a-changing \u2013 A refined proposal for finite HBV nucleos(t)ide analogue therapy","volume":"75","author":"Berg","year":"2021","journal-title":"J Hepatol"},{"issue":"6","key":"10.1016\/j.clinre.2025.102566_bib0041","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1002\/hep.31440","article-title":"Risk scores for hepatocellular carcinoma in chronic Hepatitis B: a promise for precision medicine","volume":"72","author":"Papatheodoridis","year":"2020","journal-title":"Hepatology"}],"container-title":["Clinics and Research in Hepatology and Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000464?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2210740125000464?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T11:38:24Z","timestamp":1762601904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2210740125000464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2210740125000464"],"URL":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102566","relation":{},"ISSN":["2210-7401"],"issn-type":[{"type":"print","value":"2210-7401"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term virological and clinical evaluation of chronic hepatitis B patients under nucleos(t)ide analogues therapy","name":"articletitle","label":"Article Title"},{"value":"Clinics and Research in Hepatology and Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinre.2025.102566","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102566"}}